Viewing results 1 - 6 of 7

Tajikistan’s Pharmaceutical Sector Remains Heavily Dependent on Imports

Despite possessing vast reserves of medicinal plants, Tajikistan's pharmaceutical industry remains heavily reliant on imports. Experts are increasingly questioning why the sector has been reduced to a basic "buy-and-sell" model and what is hindering the use of the country’s natural resources. Abundant Resources, Limited Output Tajikistan is home to more than 3,500 species of medicinal plants, including licorice, mint, valerian, chamomile, motherwort, and even rare saffron. However, this natural wealth has not translated into pharmaceutical independence. In the past two years alone, Tajikistan has imported roughly $84 million worth of medicines. Currently, 67 pharmaceutical companies are registered in the country, producing around 600 types of drugs. Still, imported pharmaceuticals dominate the market. According to industry observers, the sector has evolved into a retail-focused trade, rather than a hub for research-based production. During the Soviet era, pharmaceuticals in Tajikistan were closely integrated with scientific institutions. Research institutes flourished, pharmacies compounded custom medications, and both training and quality control were rigorous. Following the collapse of the USSR, this infrastructure disintegrated. The responsible state committee was dissolved, and a previously regulated system was replaced by an unstructured market. Today, training programs are often accelerated, pharmacists’ qualifications are inconsistent, and the emphasis has shifted from treatment to sales. A Pharmacy That Heals Amid this decline, one notable exception is found in the city of Isfara, where a phytotherapy department has been established at the local hospital. Spearheaded by pharmacist Abubakr Faiziev, the department operates out of a restored facility where locally gathered herbs are used to produce traditional infusions and decoctions. Faiziev personally collects about half of the ingredients. “It is important to me that the pharmacy heals, not just sells,” he said. According to Faiziev, approximately 80% of patients return for follow-up treatment, often bypassing conventional doctors due to the perceived effectiveness of herbal therapies, a sentiment echoed even among members of the local elite. A Science in Decline Faiziev laments the erosion of scientific ambition in the country. "People now ask for business plans and guaranteed profits instead of pursuing knowledge. But science doesn’t work that way," he said. Research, he noted, has become sporadic and often relies on outdated data, with little interest from private companies in investing in innovation. Young professionals, too, are increasingly opting for commercial routes. “They prefer to open pharmacies for fast income rather than engage in research,” he explained. “There are many pharmacists now. But we must transform quantity into quality. Without passion for the profession, one cannot become a skilled expert.” The State’s Role and Untapped Potential President Emomali Rahmon has repeatedly stressed the need to develop the domestic pharmaceutical industry and better utilize Tajikistan’s natural resources. Ongoing reforms include updates to medical university curricula, the opening of laboratories, and the training of technologists and quality control specialists. Yet, experts argue that without a comprehensive, systematic strategy and active engagement from the private sector, these measures are insufficient. Faiziev advocates for the creation of a pharmaceutical technology park and the development of both the domestic...

Top Kyrgyz Heart Surgeon Warns of Critical Infrastructure Shortfalls Costing Lives

Prominent heart surgeon Kaldarbek Abdramanov has issued a stark warning about the dire state of cardiac care in Kyrgyzstan, stating that thousands of lives are being lost due to the lack of adequate medical infrastructure. His urgent appeal, posted on Facebook, has sparked widespread public concern. Abdramanov emphasized that while Kyrgyz cardiac surgeons have performed more than 70,000 heart surgeries since the country’s first operation in 1959, systemic failures are now threatening the field’s progress. “Although we do not yet perform heart transplants, which is every cardiac surgeon’s dream, this is due to a lack of proper infrastructure and equipment, not knowledge,” he wrote. The surgeon recalled a fire last winter at the Research Institute of Heart Surgery and Organ Transplantation, which left the facility severely damaged. Since then, staff have been working in makeshift, substandard conditions not suited for complex procedures. He criticized the international aid programs targeted at the center as largely symbolic, offering little real assistance. “We are the students and followers of the great Isa Akhunbaev. We’ve conducted 70,000 heart surgeries and perform nearly all procedures that clinics in Europe and the U.S. do. We have the expertise and the specialists, but not the environment to support our work,” Abdramanov stated. He called for the urgent construction of a new, modern cardiology complex with at least 250 beds. “Yes, such facilities are expensive. But no cost is higher than the lives of hundreds or thousands of citizens who die each year due to the absence of this kind of center,” he warned. Abdramanov also voiced frustration with foreign medical missions, accusing them of offering superficial support. “They come and perform basic surgeries that our young specialists could handle. They don’t teach us new technologies and they don’t leave behind any equipment. This is not real help,” he said. His remarks come amid political fallout in the health sector. President Sadyr Japarov recently publicly criticized Health Minister Erkin Chechebaev for failing to manage the country's hospitals effectively. The president was informed that 24 children with critical heart conditions are awaiting surgery, with three deaths reported in recent days.

Uzbekistan and Hungary Use Nobel-Winning Discovery to Develop Health Supplements

Scientists from Uzbekistan and Hungary are collaborating to develop new health supplements derived from sweet wormwood (Artemisia annua), a plant known for its medicinal properties. The research is being conducted by the Pharmaceutical Institute of Tashkent and Hungary’s Meditop Pharmaceutical Ltd. The project is based on the groundbreaking work of Chinese scientist Tu Youyou, who won the 2015 Nobel Prize in Physiology or Medicine for discovering artemisinin, a compound extracted from sweet wormwood that effectively treats malaria. The joint initiative aims to produce antiseptic and anti-inflammatory supplements in various forms, including capsules, ointments, hydrogels, mouthwashes, and ear drops. These products are classified as food supplements rather than medicines. Currently, researchers are testing the active compounds on animals to evaluate their effectiveness. While still in the early stages of development, with prototypes being tested, mass production is planned to take place in Uzbekistan using Hungarian pharmaceutical expertise. It remains uncertain whether all prototypes will reach large-scale production, but both sides express optimism about the project’s potential. This collaboration is part of a broader partnership between the two countries. In 2023, Hungarian Foreign Minister Péter Szijjártó and Uzbek Minister of Investment, Industry, and Trade Laziz Kudratov announced plans to establish a special industrial zone in Uzbekistan for Hungarian companies. Sweet wormwood has been used in traditional medicine for centuries, particularly in Chinese medicine, where it has been employed to treat fever and infections. In recent years, artemisinin has been investigated not only for malaria treatment but also for its potential applications in cancer therapy and respiratory health, including during the COVID-19 pandemic.

Kazakhstan Cancer Drug Could Hit the Market This Year

Kazakhstan’s Minister of Science and Higher Education, Sayasat Nurbek, has announced the development of a domestic anti-cancer drug currently undergoing clinical trials. According to Nurbek, Phase II clinical trials were completed in 2023, and the number of patients participating in the testing has since been significantly expanded. "At the moment, the drug is being tested on different types of cancer. Last year, trials were conducted exclusively on patients with colorectal cancer. By the end of 2024, we expect the drug to be officially registered and introduced to the market. Preliminary results indicate stable positive dynamics," the minister stated. He noted that patients in clinical trials have experienced remissions, with tumor sizes decreasing by an average of 30%. "By the end of the year, we plan to hold a conference to present the results. The Ministry of Health has been highly supportive, and we have optimized the registration process without violating regulations," Nurbek added. The official registration of the drug is expected to be finalized as soon as possible. Kazakhstan's development of its first domestically produced anti-cancer drug was first reported in January 2024. Later, Nurbek provided updates on the trial progress and expressed confidence in the drug’s effectiveness.

Kyrgyzstan Gears Toward Self-Sufficiency in Medication

Kyrgyzstan has taken a significant step toward reducing its dependence on imported pharmaceuticals with the launch of domestic medicine production at the Aidan Pharma pharmaceutical plant. The facility has begun manufacturing its first batch of essential medications, including: Paracetamol (suspensions and tablets); Ibuprofen (suspensions); Acetylsalicylic acid (tablets); and Acyclovir (tablets). The plant has the capacity to produce up to 10,000 packages of each of these medicines per day, offering an important boost to the country’s pharmaceutical industry. In late 2023, Aidan Pharma began producing medical ethyl alcohol, which is now supplied to state hospitals and pharmacies. During a visit to the plant on January 10, Health Minister Alymkadyr Beishenaliev announced plans to expand the plant’s product range to 100 items by the end of this year. He also revealed that the company intends to begin exporting its products in the future. “The plant's products meet quality standards and have a low production cost, making them more affordable compared to imported medicines,” Beishenaliev noted. The Kyrgyz government has prioritized reducing the country’s reliance on imported medications. In December 2024, the Cabinet of Ministers approved an investment agreement for a Kyrgyz-Chinese pharmaceutical project led by Standard Pharm Group. This initiative will focus on packaging pharmaceuticals and constructing a new pharmaceutical plant in Kyrgyzstan. The project, which will be implemented in two stages over five years, is expected to attract over $41 million in investment. According to Minister of Economy and Commerce Bakyt Sydykov, the plant will manufacture a range of medicines, including: Nutritional infusions; Antibacterial, anti-inflammatory, and antipyretic medications; Analgesics; Hypoglycemic treatments; and Gastrointestinal drugs. Most of these medicines are included in Kyrgyzstan’s List of Vital Medicines, a critical inventory of essential pharmaceuticals that are currently not produced domestically. The development of Kyrgyzstan’s pharmaceutical industry marks a critical shift toward self-sufficiency in healthcare. By expanding domestic production, the government aims to make essential medications more accessible and affordable for its population while fostering economic growth through investment and exports.

Swiss Company Roche to Produce Anti-Cancer Drugs in Almaty

On October 24, the Swiss pharmaceutical giant F. Hoffmann-La Roche Ltd., in partnership with Nobel Almaty Pharmaceutical Factory JSC, launched the production of innovative drugs in Almaty. The project followed an agreement between Roche, Kazakhstan’s SK-Pharmacy LLP, Nobel, and the Kazakh Research Institute of Oncology and Radiology, with the support of National Company Kazakh Invest. Under the agreement, Roche committed to establishing local production of three biotechnological drugs for the treatment of HER2-positive breast cancer, an aggressive form of the disease that affects up to 20% of breast cancer patients in Kazakhstan. At the opening ceremony, Kazakhstan's Minister of Health, Akmaral Alnazarova, said: "The localization [of production] of oncological drugs by a global leader like Roche is a huge step forward for our country. This project will provide patients access to advanced treatments and significantly contribute to developing Kazakhstan's healthcare infrastructure.” The transfer of Roche's advanced technologies and production capabilities to local partners will reduce healthcare system costs in Kazakhstan and significantly expand patient access to essential medicines. Around 5,000 new cases of breast cancer are registered in the country annually, with approximately 1,200 resulting in death. This project is expected to increase the number of patients receiving therapy to 1,335 by 2026. The project is part of Kazakhstan’s plan to increase the share of domestically produced medicines and medical devices to 50%.